
Trevena
Clinical stage biopharmaceutical company discovering and developing g-protein coupled receptors (gpcr) biased ligands.
Market cap
$238k
Enterprise value
$24m
Share price
$0.00 TRVN
Authorizing premium user...
Clinical stage biopharmaceutical company discovering and developing g-protein coupled receptors (gpcr) biased ligands.